Charles A. Carter has established himself in both in academia and the pharmaceutical industry. He is currently serving as Professor and Chair of the Department of Pharmaceutical & Clinical Sciences in the College of Pharmacy & Health Sciences at Campbell University from 2022. Within this role, Dr. Carter oversees the educational programs for both undergraduate and graduate students in Pharmaceutical Sciences and Clinical Research. Moreover, the Department plays a pivotal role in the foundational education of Doctor of Pharmacy (PharmD) students. Professionally, Dr. Carter provides teaching, mentorship, and advisory activities for students and graduates in each of these programs and works alongside an incredible team of individuals.
Dr. Carter's academic journey is marked by several achievements. He earned his PharmD degree from the College of Pharmacy at the University of Tennessee Center for Health Sciences in 1983, following his Bachelor of Science in Pharmacy from the State University of New York at Buffalo in 1981. Dr. Carter's completed his fellowship training in Research Design and Methodology, as well as a residency in Bioinformatics and Drug Information, both at the University of Tennessee. Driven by his passion for entrepreneurialism, continuous learning, and innovation, he furthered his education with a Master in Business Administration (MBA) from Christian Brothers University in 1994.
Prior to his arrival at Campbell University in 2015, Dr. Carter held influential roles in the pharmaceutical industry, particularly in medical affairs, regulatory affairs, strategic consulting, and clinical research. He served as the Executive Director of Medical Affairs at Salix Pharmaceuticals, Inc., where he led initiatives aimed at advancing medical education, scientific communications, and research endeavors in the discovery and development of new pharmaceutical products.
Dr. Carter founded Pharmaceutical Strategic Initiatives, LLC (PSI) in 1994 based on a business plan established during his MBA training program. For nearly 20 years, he focused his energies on the company's vision and services prior to selling the organization. PSI was a provider of strategic consulting, clinical research design and strategy, regulatory preparation, medical and scientific content creation, health outcomes research, key opinion leader and advocacy development for the pharmaceutical and biopharmaceutical industries at a global level.
Dr. Carter's professional accomplishments are underscored by his research contributions and international collaborations. He has played a pivotal role as an investigator in numerous Phase 3 and Phase 4 clinical trials, as well as health economics and outcomes research studies. With over fifty publications to his name and a track record of presenting at national and international conferences, Dr. Carter has shaped the landscape of pharmaceutical development through expertise, leadership, and dedication in a very dynamic and complex world.
